CRISPR Therapeutics AG (NASDAQ: CRSP) In 2025: Reward Or Shame To Investors?
In today’s recent session, 1.79 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.75. Most recently the company’s
In today’s recent session, 1.79 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.75. Most recently the company’s
In recent trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 1.65 million shares changing hands at last check today with its beta currently measuring 1.74. Company’s
In the last trading session, 1.48 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.76. With the company’s per share
In last trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 1.4 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price
CRISPR Therapeutics AG (NASDAQ: CRSP) expects to submit an application for gene therapy approval by the end of the year. This medicine already earned good
© 2024, Powered by Smart TechOne